1. Home
  2. TECH vs CYTK Comparison

TECH vs CYTK Comparison

Compare TECH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

N/A

Current Price

$72.45

Market Cap

11.4B

Sector

Health Care

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$72.47

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TECH
CYTK
Founded
1976
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4B
10.7B
IPO Year
1995
2004

Fundamental Metrics

Financial Performance
Metric
TECH
CYTK
Price
$72.45
$72.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
19
Target Price
$71.82
$89.26
AVG Volume (30 Days)
2.4M
1.8M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
0.62%
N/A
EPS Growth
152.17
N/A
EPS
1.16
N/A
Revenue
$1,215,039,000.00
$13,368,000.00
Revenue This Year
$2.49
$7.37
Revenue Next Year
$6.40
$310.19
P/E Ratio
$62.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.20
$47.22
52 Week High
$72.62
$88.31

Technical Indicators

Market Signals
Indicator
TECH
CYTK
Relative Strength Index (RSI) 64.96 42.80
Support Level $71.89 $73.34
Resistance Level $72.62 $79.73
Average True Range (ATR) 0.18 2.22
MACD -0.20 -0.38
Stochastic Oscillator 57.29 39.09

Price Performance

Historical Comparison
TECH
CYTK

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: